glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
=== Cleaning === Cleaning of human remains varies by type. If necessary, surface cleaning of bone can be done with a very mild detergent and water solution, but bones should never be soaked in order to prevent dirt from becoming embedded in pores. The possibility of cleaning human remains is highly dependent on the fragility of the specimen.
== History == In the early 1920s, several groups noted that pancreatic extracts injected into diabetic animals would result in a brief increase in blood sugar prior to the insulin-driven decrease in blood sugar. In 1922, C. Kimball and John R. Murlin identified a component of pancreatic extracts responsible for this blood sugar increase, terming it "glucagon", a portmanteau of "glucose agonist". In the 1950s, scientists at Eli Lilly isolated pure glucagon, crystallized it, and determined its amino acid sequence. This led to the development of the first radioimmunoassay for detecting glucagon, described by Roger Unger's group in 1959. A more complete understanding of its role in physiology and disease was not established until the 1970s, when a specific radioimmunoassay was developed. In 1979, while working in Joel Habener's laboratory at Massachusetts General Hospital, Richard Goodman collected islet cells from Brockman bodies of American anglerfish in order to investigate somatostatin. By splicing DNA from anglerfish islet cells into bacteria, Goodman was able to identify the gene which codes for somatostatin. P. Kay Lund joined the Habener lab and used Goodman's bacteria to search for the gene for glucagon. In 1982, Lund and Goodman published their discovery that the proglucagon gene codes for three distinct peptides: glucagon and two novel peptides. Graeme Bell at Chiron Corporation led a team which isolated the two latter peptides, which are now known as glucagon-like peptide-1 and glucagon-like peptide-2.
It was determined that this preparation behaved anomalously in certain immunoassays and was not suitable as an IS. Three different human pituitary extracts containing prolactin were subsequently obtained as candidates for an IS. These were distributed into ampoules coded 83/562, 83/573, and 84/500. Collaborative studies involving 20 different laboratories found little difference between these three preparations. 83/562 appeared to be the most stable. This preparation was largely free of dimers and polymers of prolactin. On the basis of these investigations, 83/562 was established as the Second IS for human prolactin. Once stocks of these ampoules were depleted, 84/500 was established as the Third IS for human prolactin. 84/500 has nearly run out and in 2016 replacement was proposed. The new 83/573 contains 67.2 mIU per ampoule when calibrated against the third IS and contains 1.002 g of human pituitary extract each (which is then lyophilized). Each ampoule contains approximately 3.2 μg of prolactin. The assigned value will be 67 mIU per ampoule. If a fifth IS is needed, it will likely be based on recombinant protein, as WHO has not received any further donations of human pituitary extracts.
=== Analogs === Acetildenafil and other synthetic structural analogs of sildenafil which are PDE5 inhibitors have been found as adulterants in a number of "herbal" aphrodisiac products sold over-the-counter. These analogs have not undergone any of the rigorous testing that drugs like sildenafil have passed, and thus have unknown side-effect profiles. Some attempts have been made to ban these drugs, but progress has been slow so far, as, even in those jurisdictions that have laws targeting designer drugs, the laws are drafted to ban analogs of illegal drugs of abuse, rather than analogs of prescription medicines. However, at least one court case has resulted in a product being taken off the market. The US Food and Drug Administration (FDA) has banned numerous products claiming to be Eurycoma longifolia that, in fact, contain only analogs of sildenafil. Sellers of such fake herbals typically respond by just changing the names of their products.
Sources: en.wikipedia.org
Further work was needed to develop a ration that did not require re-hydration (thus not requiring additional preparation time and water). Further effort, led by Dr. Rauno A. Lampi, Chief of Food Systems Equipment Division at the Natick Soldier Research, Development and Engineering Center, concentrated on the refinement of the retort pouch to contain a wet ration with a three-to-ten year shelf life that could be easily shipped, carried in the field, opened and consumed straight out of the package if necessary with no further heat or water. The resulting MRE went into special issue starting in 1981 and standard issue in 1986, using a limited menu of twelve entrées.
In oxidative phosphorylation, electrons are transferred from an electron donor such as NADH to an acceptor such as O2 through an electron transport chain, releasing energy. In photophosphorylation, the energy of sunlight is used to create a high-energy electron donor which can subsequently reduce oxidized components and couple to ATP synthesis via proton translocation by the electron transport chain. Photosynthetic electron transport chains, like the mitochondrial chain, can be considered as a special case of the bacterial systems. They use mobile, lipid-soluble quinone carriers (phylloquinone and plastoquinone) and mobile, water-soluble carriers (cytochromes). They also contain a proton pump. The proton pump in all photosynthetic chains resembles mitochondrial Complex III. The commonly held theory of symbiogenesis proposes that both organelles descended from bacteria.
== Research == The Life Sciences Institute is a multidisciplinary basic science research institute, with focal strengths in chemical and structural biology. Its 23 faculty members lead labs specializing in a wide range of life sciences disciplines, including:
=== Key challenges === LEDs require optimized efficiency to hinge on ongoing improvements such as phosphor materials and quantum dots. The process of down-conversion (the method by which materials convert more-energetic photons to different, less energetic colors) also needs improvement. For example, the red phosphors that are used today are thermally sensitive and need to be improved in that aspect so that they do not color shift and experience efficiency drop-off with temperature. Red phosphors could also benefit from a narrower spectral width to emit more lumens and becoming more efficient at converting photons. In addition, work remains to be done in the realms of current efficiency droop, color shift, system reliability, light distribution, dimming, thermal management, and power supply performance. Early suspicions were that the LED droop was caused by elevated temperatures. Scientists showed that temperature was not the root cause of efficiency droop. The mechanism causing efficiency droop was identified in 2007 as Auger recombination, which was taken with mixed reaction. A 2013 study conclusively identified Auger recombination as the cause.
Kevin Billings, Honorary Group Captain, 601 (County of London) Squadron, Royal Auxiliary Air Force. For services to the Royal Air Force in the United States of America and the UK. Paul Britton, Chair, Tate Americas Foundation. For services to the arts and to philanthropy. Kevin Burke, Arts Philanthropist and Board Member, BAFTA Hong Kong Advisory Board. For services to charity and to philanthropy. Philip Hugh Davies, Principal, Philip Davies (Heritage and Planning) Ltd. For services to UK and Commonwealth Heritage. Luke Dearden, lately Political Counsellor, UK Delegation to NATO, Brussels, Belgium. For services to British Foreign and Security Policy. Duncan Edwards, Chief Executive Officer, BritishAmerican Business, and Honorary Director, The St. George's Society, New York, United States of America. For services to UK/US Trade relations and to charity. Lieutenant Colonel (Rtd) Michael Edwards, lately Senior Reports Officer, Ceasefire and Transitional Security Arrangements Monitoring and Verification Mechanism, Juba, South Sudan. For services to peace in South Sudan. Brian Hancock, Surgeon, Wythenshaw Hospital; Founding Member and Trustee, Uganda Childbirth Injury Fund. For services to surgery in Sub-Saharan Africa. Susan Hannam, Vice President, CUDECA Hospice Foundation, Spain. For services to palliative care and volunteering services in Spain. Laura Hickey, lately Director Multilateral and Human Rights, Foreign, Commonwealth and Development Office. For services to crisis management and British Foreign Policy.
Sources: en.wikipedia.org
== Laboratory directors == Clinical laboratories in the US that perform high complexity testing require a high complexity laboratory director (HCLD) who has earned a doctoral degree in chemical, physical, biological, or clinical laboratory science from an accredited institution and is certified by, and remains certified by, a board approved by HHS. The current approved boards are the following:
Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. Typically, long-term use is only recommended for pain due to cancer. It may be used by mouth or by injection into a vein, muscle, or under the skin. Effects generally begin within half an hour and last for up to five hours. A 2016 Cochrane review (updated in 2021) found little difference in benefit between hydromorphone and other opioids for cancer pain. Common side effects include dizziness, euphoria, sleepiness, nausea, itchiness, and constipation. Serious side effects may include abuse, low blood pressure, seizures, respiratory depression, and serotonin syndrome. Rapidly decreasing the dose may result in opioid withdrawal. Generally, use during pregnancy or breastfeeding is not recommended. Hydromorphone exerts its effects by activating opioid receptors, mainly in the brain and spinal cord. Hydromorphone 2 mg IV is equivalent to approximately 10 mg morphine IV. Hydromorphone was patented in 1923. Hydromorphone is made from morphine. Hydromorphone is a therapeutic alternative on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 233rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
CD123), CLEC4C, and Neuropilin, and 5) failure to express certain marker proteins that are commonly expressed by myeloid, lymphoid, and NK cell lineages. Blastic plasmacytoid dendritic cell neoplasm typically arises after the serial acquisition of multiple genetic abnormalities in pDC or their precursor cells. Inactivating mutations (i.e. mutations which cause the gene to make no or a less active product) in the TET2 gene are the most common genetic abnormality in the disease, occurring in 32–67% of all BPDCN cases and often accompanied by mutations in either the NPM1 or SRSF2 gene. Numerous other genetic abnormalities are associated with the disease: 1) mutations in NRAS, ASXL1, and TP53; 2) deletions of the CDKN2A-ARF-CDKN2B locus on the short arm of chromosome 9, CDKN1B locus on the short arm of chromosome 12, RB1 locus on the long arm of chromosome 13, or NRC1 locus on the long arm of chromosome 5; 3) fusions of KMT2A on the long arm of chromosome 11 with MLLT1 on the short arm of chromosome 10, SUPT3H on the short arm of chromosome with MYC on the long arm of chromosome 8, or KMT2A on the long arm of chromosome 11 with MLLT1 on the long arm of chromosome 19; and 4) duplication or loss of entire chromosomes, particularly chromosomes 9, 13, or 15. Laboratory studies indicate that malignant pDC have a pathologically overactive NF-κB pathway that promotes their survival and production of various cytokines) that stimulate their own proliferation.
=== GLMA: Health Professionals Advancing LGBTQ Equality === GLMA: Health Professionals Advancing LGBTQ Equality is the world's largest and oldest LGBTQ healthcare professionals association founded in 1981. It is also formerly known as the Gay and Lesbian Medical Association. GLMA provides resources along with educational programs to help healthcare professionals gain the knowledge and skills in giving appropriate care to LGBTQ patients whilst hosting conferences and workshops to foster the environment for discussion of the latest research or emerging issues in the field. They also conduct LGBTQ centered research to identify the disparities and health needs to publish guidelines and inform about evidence-based healthcare practices and policies to LGBTQ health.
=== United States === In the United States, biomedical waste is usually regulated as medical waste. In 1988 the U.S. federal government passed the Medical Waste Tracking Act which allowed the EPA to establish rules for management of medical waste in some parts of the country. After the Act expired in 1991, responsibility to regulate and pass laws concerning the disposal of medical waste returned to the individual states. The states vary in their regulations from none to very strict. In addition to on-site treatment or pickup by a biomedical waste disposal firm for off-site treatment, a mail-back disposal option allows generators of waste to return it to the manufacturer. For instance, waste medicines and equipment can be returned. The waste is shipped through the U.S. postal service. While available in all 50 U.S. states, mail-back medical waste disposal is limited by very strict postal regulations (i.e., collection containers must comply with requirements set out by the Food and Drug Administration, while shipping containers must be approved by the postal service for use).
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。